ID: ALA101022

Max Phase: Preclinical

Molecular Formula: C15H13NOS

Molecular Weight: 255.34

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCc1ccc(/C=C2/C(=O)Nc3ccccc32)s1

Standard InChI:  InChI=1S/C15H13NOS/c1-2-10-7-8-11(18-10)9-13-12-5-3-4-6-14(12)16-15(13)17/h3-9H,2H2,1H3,(H,16,17)/b13-9+

Standard InChI Key:  MFRZHGSWQHNIEA-UKTHLTGXSA-N

Associated Targets(non-human)

Vascular endothelial growth factor receptor 2 134 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 255.34Molecular Weight (Monoisotopic): 255.0718AlogP: 3.80#Rotatable Bonds: 2
Polar Surface Area: 29.10Molecular Species: NEUTRALHBA: 2HBD: 1
#RO5 Violations: 0HBA (Lipinski): 2HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.30CX Basic pKa: CX LogP: 4.27CX LogD: 4.27
Aromatic Rings: 2Heavy Atoms: 18QED Weighted: 0.81Np Likeness Score: -1.12

References

1. Vieth M, Cummins DJ..  (2000)  DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors.,  43  (16): [PMID:10956210] [10.1021/jm990609e]

Source